Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Arch Iran Med. 2022 Feb 1;25(2):133-138. doi: 10.34172/aim.2022.23.
Hepatocellular carcinoma (HCC) is the second leading cause of death due to cancer. Liver transplantation, surgical liver resection, chemotherapy, and radiotherapy are the main options for the treatment of HCC. However, these methods are unable to limit the growth, survival, and metastasis of HCC cells. Several signaling pathways control propagation, metastasis, and recurrence of HCC. Recent studies have established new approaches for the prevention and treatment of HCC using miRNA technology. MicroRNAs are a class of non-coding RNAs with an average of 22 nucleotides that play critical roles in controlling gene expression in a variety of biological processes. miRNAs can induce or suppress HCC proliferation, migration, metastasis, and tumorigenesis. The anti-cancer effects of molecular agents can be evaluated directly in animal models or indirectly through the injection of HCC cell lines treated with anti-cancer agents. Targeting cancer-specific signaling pathways with miRNAs can be novel therapeutic strategies against HCC. This study provides the latest findings on using miRNAs in the control of HCC in both and models.
肝细胞癌（HCC）是癌症死亡的第二大主要原因。肝移植、手术肝切除、化疗和放疗是治疗 HCC 的主要选择。然而，这些方法无法限制 HCC 细胞的生长、存活和转移。几种信号通路控制 HCC 的增殖、转移和复发。最近的研究利用 miRNA 技术为 HCC 的预防和治疗建立了新的方法。miRNAs 是一类平均具有 22 个核苷酸的非编码 RNA，在多种生物过程中控制基因表达中起着关键作用。miRNAs 可以诱导或抑制 HCC 的增殖、迁移、转移和肿瘤发生。通过在动物模型中直接评估分子药物的抗癌作用或通过注射用抗癌药物处理的 HCC 细胞系间接评估，可评估抗癌药物的抗癌效果。针对 HCC 特异性信号通路的 miRNA 可以成为一种针对 HCC 的新型治疗策略。本研究提供了 miRNA 在 和 模型中控制 HCC 的最新研究结果。
